In this study, we use metataxonomics to longitudinally characterize the vaginal bacterial composition from as early as 6 weeks of gestation in women at high (n?=?38) and low (n?=?22) risk of preterm b
To investigate the evidence for therapeutic efficacy of the bispecific antibodies scFv-Fc Ab 2-7/Ab 12 which serves as a foundation for the future development of broadly reactive bispecific antibodies
